

Uppsala 2001-04-11

PRESS RELEASE

PYROSEQUENCING AB PROVIDES FAST ANSWERS IN CLINICAL RESEARCH AND FORENSICS

--Company introduces a new solution for Sequence Analysis --



Uppsala, Sweden, April 11, 2001—Pyrosequencing AB (SSE:PYRO A), today announced the availability of a new solution for DNA sequence analysis that provides fast answers in clinical research and forensic investigations. The analysis of specific DNA sequences is used increasingly in areas such as clinical microbiology to improve the diagnosis and treatment of infectious diseases and in forensics for the identification of a DNA sample in an investigation. In these areas, fast results are often a critical factor. Samples can now be processed in parallel within less than one hour using new Sequence Analysis Software and Reagent Kits together with the Company's well-established PSQ™96 System for DNA sequencing.

"We see a great potential for Pyrosequencing to become a routine tool in clinical microbiology," says Professor Lars Engstrand of the Department of Medical Sciences, Clinical Bacteriology, Uppsala University. "With conventional techniques it can take days to identify or characterize bacteria or viruses. The simplicity and reliability of Pyrosequencing's sequence analysis products can shorten this to a few hours."

"This new application follows on rapidly from the success of our first products for SNP analysis which, in less than one year, have become established and recognized worldwide for their accuracy, reliability and ease of use," said Erik Walldén, President and CEO of Pyrosequencing AB. "It is also further evidence of the broad utility of our Pyrosequencing™ technology for all areas of applied genetic analysis. We believe that the unique attributes of our technology platform are

PYROSEQUENCING AB
VALLONGATAN 1, SE-752 28 UPPSALA, SWEDEN
PHONE +46 18 56 59 00, FAX +46 18 59 19 22
info@pyrosequencing.com, www.pyrosequencing.com
www.pyrosequencing.com

U.S. OFFICE:
2200 West Park Drive, Westborough, MA 01581
PHONE 1 877 797 6767, FAX 1 508 898 3306
info@pyrosequencing.com,



equally well suited for developing solutions in molecular diagnostics and we continue to explore applications for this market."

Marie Allen, Assistant Professor at the Department of Genetics and Pathology/Medical Genetics, Rudbeck Laboratory, Uppsala, Sweden works with this new technology in her role as a forensic investigator: "After only three months testing, we already use Pyrosequencing to get the answers we need for our ongoing casework. We get much faster results compared to our existing techniques and they are more easily interpreted."

"The need for fast analysis of gene-specific sequences is of increasing importance in both clinical and criminal investigations," adds Mårten Winge, VP World Wide Marketing and Support. "This new solution will provide a unique opportunity for clinical and forensic laboratories to use the latest genetic analysis technology for faster analysis and increased confidence in the results."

Pyrosequencing continues to receive orders for its PSQ™ 96 System, which has rapidly penetrated the European, U.S., and Japanese markets. The accuracy and reliability of applications based on Pyrosequencing™ technology has already been proven in the field of SNP analysis- single nucleotide polymorphisms: the most common variation found in genetic material. The PSQ 96 System can perform rapid, accurate and reproducible SNP analysis and Sequence Analysis—the analysis of DNA sequences used for identification and characterization- by simply selecting the appropriate software and reagents.

About Pyrosequencing AB

Pyrosequencing AB develops, manufactures and sells complete solutions for applied genetic analysis based on its proprietary Pyrosequencing™ technology, a simple-to-use DNA sequencing technique. In the post-genome era, Pyrosequencing's technology has established the Company as one of the leading suppliers of solutions for accurate, consistent DNA analysis in research institutions and pharmaceutical, genomics and agbiotech companies.

For the analysis of single nucleotide polymorphisms (SNPs) the PSQ™96 System with SNP Software and SNP Reagent Kits is used by customers such as AstraZeneca, GlaxoSmithKline, the Harvard Center for Cancer Prevention, the National Institutes of Health (NIH), DuPont Agriculture, and the National Cancer Centre (NCC) in Japan. The Company's Sequence Analysis Software and Reagent Kits together with the PSQ 96 System are used for the analysis of specific DNA sequences for applications such as bacterial and viral typing where speed and ease of use are essential.

The Company is headquartered in Uppsala, Sweden with North American operations located in Westborough, Massachusetts. Pyrosequencing AB also has sales offices and distribution partners in Europe, Japan and the Middle East. Pyrosequencing AB is listed on the OM Stockholm Exchange. The Company's web address is www.pyrosequencing.com

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "anticipate," "should," "planned," "estimated," and "potential," among others. These forward-looking statements are based on Pyrosequencing's current expectations. The Private Securities Litigation Reform Act of 1995 provides

PYROSEQUENCING AB

VALLONGATAN 1, SE-752 28 UPPSALA, SWEDEN

PHONE +46 18 56 59 00, **FAX** +46 18 59 19 22
info@pyrosequencing.com, www.pyrosequencing.com
www.pyrosequencing.com

U.S. OFFICE:

2200 West Park Drive, Westborough, MA 01581

PHONE 1 877 797 6767, **FAX** 1 508 898 3306
info@pyrosequencing.com,

a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Pyrosequencing notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Pyrosequencing's products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors

FOR FURTHER INFORMATION CONTACT:

President and CEO

Erik Walldén

Pyrosequencing AB

E-MAIL: erik.wallden@pyrosequencing.com

Phone: +46 18 565902 or 070 326 98 70

Investor Relations

Theresa McNeely

Pyrosequencing AB

E-MAIL: tmcneely@pyrosequencing-inc.com

Phone: + 1-508-389-1794

Central Marketing

Helena Nilshans

Pyrosequencing AB

E-MAIL: helena.nilshans@pyrosequencing.com

Phone: +46 18 565928

PYROSEQUENCING AB

VALLONGATAN 1, SE-752 28 UPPSALA, SWEDEN

PHONE +46 18 56 59 00, FAX +46 18 59 19 22

info@pyrosequencing.com, www.pyrosequencing.com

www.pyrosequencing.com

U.S. OFFICE:

2200 West Park Drive, Westborough, MA 01581

PHONE 1 877 797 6767, FAX 1 508 898 3306

info@pyrosequencing.com,